USANA Health Sciences, Inc. — Form 10-Q Summary
Period clarification: The request metadata says 2021 Q2, but this filing reports the quarter ended July 2, 2022, with comparative figures for the quarter ended July 3, 2021. Unless noted otherwise, amounts below are in U.S. dollars.
Business context and reporting period
USANA develops and sells nutritional, food, personal-care, and skincare products internationally through independent direct-selling Associates. It reported approximately 559,000 active Customers at July 2, 2022, down 14.3% from a year earlier. The company operates in Asia Pacific and Americas and Europe; 90.2% of first-half 2022 sales were outside the United States.
Financial performance and liquidity
| Metric | Quarter ended July 2, 2022 | Quarter ended July 3, 2021 | Six months ended July 2, 2022 | Six months ended July 3, 2021 |
|---|---|---|---|---|
| Net sales | $264.5 million | $336.8 million | $537.3 million | $644.8 million |
| Gross profit | $215.0 million | $279.8 million | $436.4 million | $530.1 million |
| Gross margin | 81.3% | 83.1% | 81.2% | 82.2% |
| Operating earnings | $29.4 million | $53.7 million | $62.4 million | $97.9 million |
| Net earnings | $19.2 million | $38.2 million | $41.6 million | $68.9 million |
| Diluted EPS | $1.00 | $1.87 | $2.15 | $3.31 |
| Operating cash flow | Not separately presented for the quarter | $34.3 million | $58.8 million |
Second-quarter sales fell 21.5% year over year, or 18.2% excluding currency effects; first-half sales declined 16.7%, or 14.5% excluding currency effects. Second-quarter diluted EPS declined 46.5%. Gross margin contracted 180 basis points in the quarter and 100 basis points in the first half.
At July 2, 2022, cash and cash equivalents were $230.4 million, total current assets were $342.0 million, and current liabilities were $133.6 million. The company had no outstanding borrowings under its $75 million revolving credit facility. First-half investing cash outflow was $5.5 million, including $6.5 million in cash paid for acquired assets; financing cash outflow was $29.9 million, including $25.4 million of share repurchases. Cash declined $9.5 million from January 1, 2022.
Stockholders’ equity was $403.7 million. The company reported a $9.9 million first-half net-of-tax other comprehensive loss, primarily reflecting foreign-currency translation. There were no off-balance-sheet arrangements.
Material changes versus the prior comparable period
- Lower active-Customer counts and weaker sales-program performance drove much of the sales decline. Active Customers fell 14.3% overall; Asia Pacific declined 14.6% and Americas and Europe declined 12.9%.
- COVID-19-related lockdowns, restrictions, and other disruptions, particularly in Asia Pacific, affected sales and operations. Management also cited timing and geographic differences in sales promotions versus the prior-year quarter, when a successful worldwide program contributed to double-digit active-Customer growth.
- Currency movements reduced second-quarter sales by an estimated $10.9 million and first-half sales by $13.7 million.
- Gross margin pressure reflected currency, inventory valuation adjustments, higher material costs, and reduced scale from lower sales. Lower sales also increased SG&A as a share of revenue, despite lower absolute SG&A expense.
- First-half operating cash flow declined from $58.8 million to $34.3 million. Management attributed the 2022 cash generation partly to earnings and noncash adjustments, offset by payment of the 2021 annual employee bonus and lower trade payables.
Outlook, risks, contingencies, and unusual items
No specific revenue or earnings guidance is provided in the supplied filing text. Management expects cash balances, operating cash flow, and available credit to cover ordinary-course operating and capital needs for the foreseeable future, while noting that adverse conditions or unusual capital requirements could require financing.
Management said COVID-19-related effects would likely continue to negatively affect the business throughout 2022 and noted inflationary pressure across several business areas. Other disclosed risks include direct-selling and China regulatory requirements, China operating and remittance restrictions, foreign-exchange volatility, supply-chain and freight disruption, geopolitical developments, data-security and privacy matters, and compliance with credit-facility covenants.
During the second quarter, USANA acquired assets in business combinations for $6.5 million in cash and $0.9 million in contingent consideration. The acquired businesses’ post-acquisition revenue and earnings were immaterial. The contingent consideration is milestone-based, with a maximum earn-out of $1.5 million. The company reported ordinary-course litigation and other contingencies that could not currently be estimated; management did not expect them, individually or together, to materially adversely affect financial condition, liquidity, or results.
The credit agreement requires rolling four-quarter consolidated EBITDA of at least $100 million and a consolidated funded-debt-to-EBITDA ratio no greater than 2.0 to 1.0. The filing states there was no outstanding facility debt at quarter-end. Management reported disclosure controls were effective and that risk factors had not materially changed from the 2021 Form 10-K.
Important facts for investors to verify
- Confirm the reporting-period discrepancy: the filing is for the quarter ended July 2, 2022, not 2021 Q2.
- Track active-Customer counts, sales-program results, and recovery trends by region, especially in China and Southeast Asia Pacific.
- Assess whether currency movements, inflation, inventory adjustments, and supply-chain costs continue to pressure sales and margins.
- Monitor operating cash flow, China cash remittance conditions, and compliance with the credit-facility EBITDA and leverage covenants.
- Review the acquired assets’ performance and the assumptions underlying the contingent-consideration liability.
- Consider that management’s liquidity assessment is forward-looking and that legal contingencies are not currently estimable.